GoPro Shares Edge Up After-Hours On 23% Layoff Announcement

• The action camera manufacturer said that the layoffs account for 23% of its global headcount of 631 employees as of the end of the first quarter. 
• For 2025, the company reported revenue of $652 million, down 19% year-over-year, as sell-through fell about 20% year-over-year.
• GoPro expects a majority of the charge, up to $8 million, to be incurred in the third quarter of 2026.

Shares of GoPro, Inc. (GPRO) edged up 1% after-hours on Tuesday after the company announced that it will layoff about 145 employees in a bid to reduce operating costs.

The action camera manufacturer said that the layoffs account for 23% of its global headcount of 631 employees as of the end of the first quarter.

The layoffs are expected to be completed by the end of 2026 and are estimated to result in a charge of $11.5 million to $15 million, including one-time termination benefits to the affected employees, the company said. GoPro expects a majority of the charge, up to $8 million, to be incurred in the third quarter of 2026.

GoPro’s Sustained Hardships

GoPro has faced significant hardships, including sustained financial losses, and intense competition from rivals like DJI and Insta360, causing its market share to drop. The company has undergone multiple rounds of layoffs to reduce operating costs in the past including a 15% reduction in August 2024.

For 2025, the company reported revenue of $652 million, down 19% year-over-year, as sell-through fell about 20% year-over-year to 2 million camera units. The company also reported an adjusted loss per share of $0.30 for the period.

How Did Retail Traders React?

On Stocktwits, retail sentiment around GPRO stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.

A Stocktwits user voiced hopes for GoPro being acquired by Meta Platforms.

Another, however, dismissed the company as a “value trap.”

GPRO stock has fallen 49% thus far this year. 

Read More: Insmed’s Experimental Skin Disease Drug Fails In Study

For updates and corrections, email newsroom[at]stocktwits[dot]com.